Another setback for Prexige
Executive Summary
The U.K., Germany and Austria pull Novartis' Prexige (lumiracoxib) from the market after the European Medicines Agency's Committee for Medicinal Products for Human Use initiates a safety review of the COX-2 inhibitor on Nov. 16. The drug was deemed "not approvable" in the U.S. by FDA in September (1"The Pink Sheet" Oct. 1, 2007, In Brief). An assessment from the CHMP is expected in December...